Roth Capital Has Bearish Estimate for Tilray FY2025 Earnings

Tilray Inc (NASDAQ:TLRY - Free Report) - Roth Capital cut their FY2025 earnings per share (EPS) estimates for Tilray in a research note issued to investors on Sunday, January 12th. Roth Capital analyst W. Kirk now forecasts that the company will post earnings of ($0.23) per share for the year, down from their previous estimate of ($0.18). The consensus estimate for Tilray's current full-year earnings is ($0.14) per share.

A number of other research analysts also recently weighed in on the company. Roth Mkm dropped their price target on Tilray from $2.00 to $1.75 and set a "neutral" rating on the stock in a research note on Friday, October 11th. Canaccord Genuity Group upped their target price on Tilray from $2.00 to $3.00 and gave the stock a "buy" rating in a research report on Monday. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Tilray has an average rating of "Hold" and a consensus price target of $2.70.

Tilray Price Performance

Shares of TLRY stock remained flat at $1.18 on Wednesday. 36,012,203 shares of the stock were exchanged, compared to its average volume of 45,037,734. The company has a current ratio of 2.47, a quick ratio of 1.57 and a debt-to-equity ratio of 0.08. The firm has a 50 day simple moving average of $1.34 and a 200-day simple moving average of $1.61. The stock has a market capitalization of $1.07 billion, a P/E ratio of -4.37 and a beta of 2.08. Tilray has a one year low of $1.14 and a one year high of $2.97.

Tilray (NASDAQ:TLRY - Get Free Report) last released its earnings results on Friday, January 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.07). The company had revenue of $210.90 million for the quarter, compared to analyst estimates of $216.34 million. Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The company's revenue was up 8.7% on a year-over-year basis.

Institutional Trading of Tilray

Institutional investors have recently made changes to their positions in the company. Arizona State Retirement System boosted its holdings in Tilray by 4.4% during the second quarter. Arizona State Retirement System now owns 216,693 shares of the company's stock worth $360,000 after purchasing an additional 9,171 shares during the last quarter. J.W. Cole Advisors Inc. boosted its stake in shares of Tilray by 1,077.2% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 171,054 shares of the company's stock worth $284,000 after buying an additional 156,524 shares during the last quarter. WINTON GROUP Ltd purchased a new position in shares of Tilray in the 2nd quarter worth approximately $83,000. Marathon Trading Investment Management LLC increased its position in shares of Tilray by 52.4% during the second quarter. Marathon Trading Investment Management LLC now owns 76,501 shares of the company's stock valued at $127,000 after acquiring an additional 26,301 shares during the last quarter. Finally, Bank of Montreal Can increased its position in shares of Tilray by 19.6% during the second quarter. Bank of Montreal Can now owns 2,169,100 shares of the company's stock valued at $3,622,000 after acquiring an additional 355,778 shares during the last quarter. Institutional investors own 9.35% of the company's stock.

Insider Activity at Tilray

In related news, CFO Carl A. Merton acquired 26,000 shares of the company's stock in a transaction on Friday, November 15th. The shares were acquired at an average cost of $1.36 per share, for a total transaction of $35,360.00. Following the purchase, the chief financial officer now owns 26,000 shares in the company, valued at approximately $35,360. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.87% of the stock is owned by insiders.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.